A federal judge tossed a lawsuit filed in 2010 accusing Medtronic (NYSE:MDT) of violating patents held by W.L. Gore & Associates covering stent graft manufacturing techniques.
Judge tosses Gore stent graft suit against Medtronic
W.L. Gore & Associates
Federal Circuit reverses part of Bard’s $371M patent win over Gore
GI Dynamics and Gore creep toward trial in weight-loss device patent dispute
A long-running dispute between W.L Gore & Associates and GI Dynamics (ASX:GID) stepped closer to trial when an Arizona District Judge affirmed that all but 1 of GI Dynamics’ counterclaims in the patent infringement lawsuit may proceed to trial.
All claims on both sides are ready for trial, and a pretrial conference between the companies is set for July. No trial date has yet been determined.
FDA panel wants a closer look at St. Jude’s Amplatzer data
An FDA panel recommended that the agency’s Center for Devices & Radiological Health re-analyze existing data for St. Jude Medical‘s (NYSE:STJ) Amplatzer heart implant during a hearing yesterday to review safety data for the Amplatzer and for W.L. Gore & Associates‘ Helex implant.
FDA panel to review St. Jude, W.L. Gore heart implants today
An FDA panel is scheduled for a hearing today to review post-market surveillance data for a pair of cardiac implants made by St. Jude Medical (NYSE:STJ) and W.L. Gore & Associates.
St. Jude and W.L. Gore heart hole closure systems get a date with the FDA
The FDA’s circulatory devices panel will review post-market data for St. Jude Medical‘s (NYSE:STJ) Amplatzer septal occluder* and W.L. Gore’s Helex septal occluder May 24 to discuss concerns about the devices after more than a decade on the U.S. market.
IBM’s Watson supercomputer tackles cancer | MassDevice.com On Call
MASSDEVICE ON CALL — IBM’s Jeopardy-winning Watson supercomputer is taking a swing at oncology research in efforts to help hospitals more quickly diagnose and treat cancer.
Watson can cull through 200 million pages of information in less than 3 seconds, according to IBM, and the machine is getting an education in oncology at Manhattan’s Memorial Sloan-Kettering Cancer Center.
MassDevice.com +3 | The top 3 med-tech stories for February 10, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
UPDATE: Wall St. reacts to Bard’s $371M win against Gore | Legal News
Updated Feb. 10, 2012, at 1:30 p.m. with share values and analysts’ reactions.
A U.S. federal judge this week upheld C.R. Bard’s (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
Court reaffirms C.R. Bard’s $371M patent win against W.L. Gore | Legal News
A U.S. federal judge this week upheld C.R. Bard’s (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard’s $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
FDA approves first endovascular grafts for aortic tears | Regulatory Roundup
The FDA granted W.L. Gore & Associates the first U.S. clearance for using an endovascular graft to treat tears or ruptures in the aortic wall.
Gore’s Conformable TAG thoracic endoprosthesis was approved as a treatment for a transection or tear in the aortic wall, an injury typically the result of a car accident, crushing of the chest or a fall from a high place, according to an FDA release.
